Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Mechanical thrombectomy for acute ischemic stroke. Main billing specialties: neurosurgery, interventional radiology and neurology.
Medicare fee-for-service stroke thrombectomy cases in the 36 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (110 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 46 | 1,384+6.8%/yr | +6.8%/yr | 0.41.0× | 0% | 1,290 in 2030−1.1%/yr |
| Florida | 32 | 1,063+2.8%/yr | +2.8%/yr | 0.51.1× | 0% | 1,080 in 2030+0.2%/yr |
| Texas | 25 | 822−0.1%/yr | −0.1%/yr | 0.40.9× | 0% | 1,230 in 2030+6.9%/yr |
| Pennsylvania | 30 | 767+7.4%/yr | +7.4%/yr | 0.61.4× | 0% | 1,030 in 2030+5%/yr |
| New York | 16 | 669+0.8%/yr | +0.8%/yr | 0.40.9× | 0% | 800 in 2030+3%/yr |
| Illinois | 25 | 589+1.7%/yr | +1.7%/yr | 0.41.0× | 0% | 610 in 2030+0.7%/yr |
| Ohio | 16 | 453−0.3%/yr | −0.3%/yr | 0.41.0× | 0% | 410 in 2030−1.6%/yr |
| North Carolina | 15 | 435−2.3%/yr | −2.3%/yr | 0.51.1× | 0% | 420 in 2030−0.8%/yr |
| Virginia | 21 | 418−0.3%/yr | −0.3%/yr | 0.40.9× | 0% | 480 in 2030+2.5%/yr |
| Georgia | 17 | 378+12%/yr | +12%/yr | 0.51.1× | 0% | 530 in 2030+5.8%/yr |
| Michigan | 9 | 361−2.8%/yr | −2.8%/yr | 0.41.0× | 0% | 360 in 2030−0.1%/yr |
| Tennessee | 10 | 360−6%/yr | −6%/yr | 0.51.2× | 0% | 300 in 2030−3%/yr |
| Massachusetts | 15 | 351+2.1%/yr | +2.1%/yr | 0.40.9× | 0% | 410 in 2030+2.8%/yr |
| New Jersey | 15 | 346+3.2%/yr | +3.2%/yr | 0.30.8× | 0% | 330 in 2030−1%/yr |
| Washington | 12 | 317+1.2%/yr | +1.2%/yr | 0.41.0× | 0% | 270 in 2030−2.8%/yr |
| Missouri | 12 | 310+5.1%/yr | +5.1%/yr | 0.51.2× | 0% | 380 in 2030+3.2%/yr |
| Maryland | 13 | 289+7.1%/yr | +7.1%/yr | 0.30.8× | 0% | 580 in 2030+12%/yr |
| Indiana | 10 | 254+3.3%/yr | +3.3%/yr | 0.40.9× | 0% | 320 in 2030+3.7%/yr |
| Arizona | 10 | 233+2.7%/yr | +2.7%/yr | 0.30.8× | 0% | 280 in 2030+3%/yr |
| Wisconsin | 8 | 221−2.1%/yr | −2.1%/yr | 0.40.9× | 0% | 160 in 2030−5.4%/yr |
| Kentucky | 7 | 209+7%/yr | +7%/yr | 0.51.1× | 0% | 340 in 2030+8.4%/yr |
| Alabama | 6 | 207+12%/yr | +12%/yr | 0.51.1× | 0% | 180 in 2030−1.9%/yr |
| Louisiana | 10 | 196+0.2%/yr | +0.2%/yr | 0.51.2× | 0% | 250 in 2030+4.2%/yr |
| Colorado | 7 | 194+4.9%/yr | +4.9%/yr | 0.41.0× | 0% | 180 in 2030−1.5%/yr |
| Oklahoma | 4 | 180+1.4%/yr | +1.4%/yr | 0.40.9× | 0% | 140 in 2030−3.7%/yr |
| Minnesota | 6 | 178−8.1%/yr | −8.1%/yr | 0.40.9× | 0% | 280 in 2030+7.8%/yr |
| Connecticut | 7 | 176+8.9%/yr | +8.9%/yr | 0.61.3× | 0% | 270 in 2030+7.2%/yr |
| South Carolina | 7 | 160−8.2%/yr | −8.2%/yr | 0.20.6× | 0% | 250 in 2030+7.6%/yr |
| Kansas | 8 | 152+1.4%/yr | +1.4%/yr | 0.40.9× | 0% | 110 in 2030−5.6%/yr |
| Iowa | 8 | 149+0.7%/yr | +0.7%/yr | 0.30.8× | 0% | 240 in 2030+8%/yr |
| Nevada | 3 | 133−3.3%/yr | −3.3%/yr | 0.51.1× | 0% | 190 in 2030+6.2%/yr |
| Oregon | 1 | 130−4.5%/yr | −4.5%/yr | 0.30.7× | 0% | 270 in 2030+13%/yr |
| Arkansas | 6 | 127−8.9%/yr | −8.9%/yr | 0.30.8× | 0% | 150 in 2030+2.3%/yr |
| Rhode Island | 4 | 113+3.8%/yr | +3.8%/yr | 1.33.0× | 0% | 120 in 2030+1.2%/yr |
| Mississippi | 3 | 111−3.4%/yr | −3.4%/yr | 0.30.7× | 0% | 170 in 2030+7.4%/yr |
| Utah | 2 | 108+8.1%/yr | +8.1%/yr | 0.51.2× | 0% | 180 in 2030+9%/yr |
Professional codes (what the surgeon bills): CPT 61645; the hospital bills MS-DRG 023, 024.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 16 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 4 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 6 |
| Stryker | 6 |
| Phenox | 3 |
| Concentric Medical | 1 |
Product codes: POL (neurovascular mechanical thrombectomy device for acute ischemic stroke treatment). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 35% of the cases CMS names in California; 33 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Aneurysm & intracranial embolization | 398 | 14,006+13%/yr | +13%/yr | 25,900 in 2030+11%/yr |
| DBS & VNS | 156 | 9,717−3.7%/yr | −3.7%/yr | 14,000 in 2030+6.2%/yr |
| CSF shunts | 56 | 5,163−4.8%/yr | −4.8%/yr | 6,290 in 2030+3.3%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 19 companies reported engagement with surgeons in the covered states worth $12M in consulting, speaking, meals and travel tied to these products, about $28K per surgeon billing it. Royalties are left out.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.